Petition Closed

Reduce to patients the cost of the drug, Gleevec.

Novatis developed this drug in the 1990s. In the years since then the price of the drug has increased astronomically. Novartis must have paid their research costs long ago, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep them alive. Our US representatives should work with FDA to pressure Novartis to reduce the cost of Gleevec.

This petition was delivered to:
  • Novartis and US Representatives in Congress


    Ruth Waldhauer started this petition with a single signature, and now has 427 supporters. Start a petition today to change something you care about.